Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((SNYNF)), Sanofi ((DE:SNW)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: The clinical study titled A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis aims to evaluate the pharmacokinetics and safety of Dupilumab in young patients with Prurigo Nodularis. This study is significant as it addresses a pediatric population for a condition that lacks extensive treatment options.
Intervention/Treatment: The study tests Dupilumab, an experimental drug administered subcutaneously. It is intended to treat Prurigo Nodularis by modulating the immune response.
Study Design: This is a Phase 3, open-label, single-group study focusing on treatment. There is no masking involved, meaning all participants and researchers know the treatment being administered.
Study Timeline: The study began on May 15, 2024, with an expected duration of approximately 42 to 44 weeks per participant. The latest update was submitted on August 19, 2025, indicating ongoing recruitment and progress.
Market Implications: The study’s progress could positively influence the stock performance of Regeneron Pharmaceuticals and Sanofi, as successful results may lead to expanded market opportunities for Dupilumab. Investors should monitor this study alongside industry trends and competitor developments.
The study is currently ongoing, with further details available on the ClinicalTrials portal.